IVF Market Players Find Acquisitions Exceptionally Fit to Grow

Entering 2016, the statistics from the Q4 2015 study shows that In vitro Fertilization (IVF) Services Market deals would continue making headlines. The research analysts weighing upon the opportunities, size and share and growth of the In vitro Fertilization (IVF) Services Market reveal that the steep rise in both the value as well as volume of the deals in 2016 will keep prominent players competitive.

There is a trend popular among working women, where many choose to postpone their pregnancy.  According to the “Fifth Malaysian Population & Family Survey”, in 2014, about 35.7% women were unmarried, as they failed to find a suitable partner for marriage. The study further outlines that 56% of men hold financial problems responsible for postponing their marriage. The situation has worsened, and is anticipated to encourage more acquisitions and mergers in 2016. So let’s discuss some of the major acquisition of 2016?

 

Cooper Cos. (COO) Invests in Recombine

The Recombine deal is definitely a turning point for Cooper Cos., active in In vitro fertilization (IVF) services market. Industry experts were glued to their television sets and newspaper, when the Cooper Companies, Inc. (NYSE: COO) cleared all doubts over CooperSurgical’s investment in different commercial assets of a genetic testing enterprise called Recombine Inc. The deal is valued at $85 million. Specializing in carrier screening Recombine has trailing 12-month revenue of close to $20 million as of April 2016.

Official sources revealed that the revenue is anticipated to grow double digit in the next five to six years. Commenting on the deal Robert S. Weiss, CEO and President, at Cooper Cos. said “This acquisition is an exceptional fit for CooperSurgical as it adds the premier carrier screening test sold within the IVF marketplace to our existing IVF genetic testing platform.” Weiss explained “This deal is also a nice strategic fit within our complete portfolio as it supports our leading IVF products and allows leverage within our ObGyn sales force.” Officials at Cooper believe the acquisition would open new opportunities for the company in the In vitro fertilization (IVF) services market.

View all the report related to medical device at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report

UAE IVF Market Remains Promising

International companies are observed buying shares of UAE-based fertility companies to tap the booming fertility industry in the region.  It all started with the MNC and Fakih IVF Group deal. An Abu Dhabi-based healthcare company shot to fame when it agreed to pay about Dh696 million to have a stake in one of the reputed fertility clinics based in the Middle East, performing over 4,000 IVF cycles every year.

The acquisition involves a mechanism by which the acquirer (NMC) can enjoy a maximum share in Fakih IVF, a privately owned clinic. Earlier this year, NMC made several heads turn when it withdrew from the bidding contest with Mediclinic to invest in Al Noor Hospitals, London. The deal of Fakih IVF will strengthen the NMC’s hold in the maternity and fertility segment, which also includes Brightpoint Royal Women’s Hospital as well as European fertility specialist Clinica Eugin. Fakih IVF, had garnered earnings of about $25m in the initial 9 months of 2015 and operates clinics in Dubai and Abu Dhabi.

B R Shetty, the chief executive at NMC health said “Our acquisition of a major shareholding in Fakih IVF is the logical next step towards achieving NMC’s goal of becoming a global leader in maternity and fertility services.” Shetty further explained “We are particularly excited about growing our in vitro fertilisation service offering within the UAE and look forward to further expand its geographic reach.”

http://www.slideshare.net/ishanshukla21/ivf-market-trends-and-an-overview

European Distributor in IVF Market Gets Acquired

BioCare a European company was acquired by Irvine Scientific, a leading manufacturer and developer of medical equipment, cell culture, reagents and others especially for research, industrial and clinical use. Serving the requirements of fertility hospitals and clinics across different countries with cGMP cell culture, Irvine has managed to build a strong presence in Europe. Over the last few years, the company has established its sales presence in countries including Germany, United Kingdom and France.

On the other hand, BioCare is a major distributor of an array of IVF products in the Europe. The company has established a strong foothold, when it comes to the sales network in the European countries such as Portugal, Italy, Spain, Greece and France. Today, the fertility market in Europe is considered to be the largest in the world and is anticipated to witness a stable development. Yuichi Nagano, the chief executive officer and president at Irvine Scientific said “With its well established network across the continent BioCare provides the connections and operations to enable us to better serve the European IVF market.”

Laser IVF is Definitely the Next Big Thing

Vitrolife recently made several heads turn, when it acquired MTG and OCTAX. Both companies hold a leading position in the laser technology segment for the IVF market. The product portfolio by OCTAX’s Laser and Imaging Systems is believed to be the largest in terms of profits. In addition, the modular concept that includes intelligent software and hardware tools developed for maximum efficiency is an important feature of the company’s product range serving the In-vitro fertilization (IVF) services market

There are many couples thinking of embarking on their journey of being proud parents. Big brands operating in In vitro fertilization (IVF) services market are making the best of the demand by exploring new regions and acquiring more and more local companies.

 

Related Post